{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:56Z","timestamp":1792686296981,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this NMA is to comprehensively analyze evidence of oral GnRH antagonist in the treatment of moderate-to-severe endometriosis-associated pain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Literature searching was performed to select eligible studies published prior to April 2022 in PubMed, Cochrane, Embase and Web of Science. Randomized controlled trials involving patients who suffered from moderate-to-severe endometriosis-associated pain and treated with oral nonpeptide GnRH antagonists or placebo were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Elagolix 400\u00a0mg and ASP1707 15\u00a0mg were most efficient in reducing pelvic pain, dysmenorrhea and dyspareunia. Relugolix 40\u00a0mg was best in reducing the analgesics use. The rates of any TEAEs and TEAEs-related discontinuation were highest in relugolix 40\u00a0mg and elagolix 250\u00a0mg, respectively, while rates of hot flush and headache were highest in relugolix 40\u00a0mg and elagolix 150\u00a0mg. Significantly decreased spinal BMD was observed in elagolix 250\u00a0mg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Oral GnRH antagonists were effective in endometriosis-associated pain in 12w, and most of the efficiency and safety outcomes were expressed in a dose-dependent manner, but linzagolix 75\u00a0mg was an exception.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-022-06862-0","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T17:05:18Z","timestamp":1674147918000},"page":"1047-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3799","authenticated-orcid":false,"given":"Lingli","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"2","key":"6862_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s0889-8545(05)70302-8","volume":"24","author":"B Eskenazi","year":"1997","unstructured":"Eskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24(2):235\u2013258. https:\/\/doi.org\/10.1016\/s0889-8545(05)70302-8","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"25","key":"6862_CR2","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1056\/NEJMcp1000274","volume":"362","author":"LC Giudice","year":"2010","unstructured":"Giudice LC (2010) Clinical practice. Endometr N Engl J Med 362(25):2389\u20132398. https:\/\/doi.org\/10.1056\/NEJMcp1000274","journal-title":"Endometr N Engl J Med"},{"key":"6862_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17134683","author":"L Della Corte","year":"2020","unstructured":"Della Corte L, Di Filippo C, Gabrielli O et al (2020) The burden of endometriosis on women\u2019s lifespan: a narrative overview on quality of life and psychosocial wellbeing. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph17134683","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"6862_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.fertnstert.2006.06.015","volume":"86","author":"X Gao","year":"2006","unstructured":"Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL (2006) Economic burden of endometriosis. Fertil Steril 86(6):1561\u20131572. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.06.015","journal-title":"Fertil Steril"},{"issue":"3","key":"6862_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/GRF.0000000000000292","volume":"60","author":"S Rafique","year":"2017","unstructured":"Rafique S, Decherney AH (2017) Medical management of endometriosis. Clin Obstet Gynecol 60(3):485\u2013496. https:\/\/doi.org\/10.1097\/GRF.0000000000000292","journal-title":"Clin Obstet Gynecol"},{"key":"6862_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bpobgyn.2018.01.015","volume":"51","author":"P Vercellini","year":"2018","unstructured":"Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E (2018) Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol 51:68\u201391","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"6862_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/humrep\/det457","volume":"29","author":"G Dunselman","year":"2014","unstructured":"Dunselman G, Vermeulen N, Becker C et al (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29(3):400\u2013412","journal-title":"Hum Reprod"},{"issue":"10","key":"6862_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-018-0928-0","volume":"78","author":"S Ferrero","year":"2018","unstructured":"Ferrero S, Barra F, Maggiore ULR (2018) Current and emerging therapeutics for the management of endometriosis. Drugs 78(10):995\u20131012","journal-title":"Drugs"},{"issue":"5","key":"6862_CR9","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1210\/jc.2016-3845","volume":"102","author":"J Ng","year":"2017","unstructured":"Ng J, Chwalisz K, Carter DC, Klein CE (2017) Dose-dependent suppression of gonadotropins and ovarian hormones by Elagolix in healthy premenopausal women. J Clin Endocrinol Metab 102(5):1683\u20131691. https:\/\/doi.org\/10.1210\/jc.2016-3845","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"6862_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-018-0977-4","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN (2018) Elagolix: first global approval. Drugs 78(14):1501\u20131508. https:\/\/doi.org\/10.1007\/s40265-018-0977-4","journal-title":"Drugs"},{"issue":"9","key":"6862_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/13543784.2021.1957830","volume":"30","author":"S Dababou","year":"2021","unstructured":"Dababou S, Garzon S, Lagana AS et al (2021) Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs 30(9):903\u2013911. https:\/\/doi.org\/10.1080\/13543784.2021.1957830","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"6862_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/humrep\/dez028","volume":"34","author":"T D'Hooghe","year":"2019","unstructured":"D\u2019Hooghe T, Fukaya T, Osuga Y et al (2019) Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod 34(5):813\u2013823. https:\/\/doi.org\/10.1093\/humrep\/dez028","journal-title":"Hum Reprod"},{"key":"6862_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane Handbook for Systematic Reviews of Interventions, 2nd edn. Wiley, Chichester, UK. https:\/\/doi.org\/10.1002\/9781119536604","edition":"2"},{"key":"6862_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"3","key":"6862_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/1933719113497292","volume":"21","author":"MP Diamond","year":"2014","unstructured":"Diamond MP, Carr B, Dmowski WP et al (2014) Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 21(3):363\u2013371. https:\/\/doi.org\/10.1177\/1933719113497292","journal-title":"Reprod Sci"},{"issue":"2","key":"6862_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","volume":"115","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N (2021) Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril 115(2):397\u2013405. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.07.055","journal-title":"Fertil Steril"},{"issue":"1","key":"6862_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa1700089","volume":"377","author":"HS Taylor","year":"2017","unstructured":"Taylor HS, Giudice LC, Lessey BA et al (2017) Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 377(1):28\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1700089","journal-title":"N Engl J Med"},{"issue":"1","key":"6862_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","volume":"114","author":"J Donnez","year":"2020","unstructured":"Donnez J, Taylor HS, Taylor RN et al (2020) Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril 114(1):44\u201355. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.02.114","journal-title":"Fertil Steril"},{"issue":"2","key":"6862_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5301\/je.5000211","volume":"7","author":"N \u00c1cs","year":"2015","unstructured":"\u00c1cs N, O\u2019Brien C, Jiang P et al (2015) Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord 7(2):56\u201362","journal-title":"J Endometr Pelvic Pain Disord"},{"key":"6862_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111342","author":"J Donnez","year":"2021","unstructured":"Donnez J, Dolmans MM (2021) GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222111342","journal-title":"Int J Mol Sci"},{"issue":"4","key":"6862_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1089\/jwh.2019.8096","volume":"30","author":"N Leyland","year":"2021","unstructured":"Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS (2021) A clinician\u2019s guide to the treatment of endometriosis with Elagolix. J Womens Health (Larchmt) 30(4):569\u2013578. https:\/\/doi.org\/10.1089\/jwh.2019.8096","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"6862_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","volume":"132","author":"E Surrey","year":"2018","unstructured":"Surrey E, Taylor HS, Giudice L et al (2018) Long-term outcomes of Elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol 132(1):147\u2013160. https:\/\/doi.org\/10.1097\/AOG.0000000000002675","journal-title":"Obstet Gynecol"},{"issue":"8","key":"6862_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1358\/dot.2019.55.8.3020179","volume":"55","author":"F Barra","year":"2019","unstructured":"Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S (2019) Relugolix for the treatment of uterine fibroids. Drugs Today (Barc) 55(8):503\u2013512. https:\/\/doi.org\/10.1358\/dot.2019.55.8.3020179","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"6862_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12905-021-01393-3","volume":"21","author":"Y Osuga","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N (2021) Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results. BMC Womens Health 21(1):250. https:\/\/doi.org\/10.1186\/s12905-021-01393-3","journal-title":"BMC Womens Health"},{"issue":"1","key":"6862_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/14397595.2020.1733214","volume":"31","author":"T Takeuchi","year":"2021","unstructured":"Takeuchi T, Tanaka Y, Higashitani C et al (2021) A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. Mod Rheumatol 31(1):53\u201360. https:\/\/doi.org\/10.1080\/14397595.2020.1733214","journal-title":"Mod Rheumatol"},{"issue":"4","key":"6862_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, Ackerman RT, Al-Hendy A et al (2020) Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med 382(4):328\u2013340. https:\/\/doi.org\/10.1056\/NEJMoa1904351","journal-title":"N Engl J Med"},{"issue":"11","key":"6862_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1177\/1933719114549848","volume":"21","author":"B Carr","year":"2014","unstructured":"Carr B, Dmowski WP, O\u2019Brien C et al (2014) Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 21(11):1341\u20131351. https:\/\/doi.org\/10.1177\/1933719114549848","journal-title":"Reprod Sci"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06862-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:07:47Z","timestamp":1692270467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06862-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["6862"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06862-0","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"28 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}